Delving into the Latest Updates on Group B Meningococcal 44/76 MOS NOMV 5D Vaccine(WRAIR) with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Walter Reed Army Institute of Research

Active Organization-

Inactive Organization

U S Army Medical Research & Development Command

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis.
This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded. This means that neither the volunteer or the medical team will know which formulation of the vaccine was administered. The third group of volunteers and the medical team will know that they are receiving the higher dose of the vaccine.

Start Date05 Dec 2005

Sponsor / Collaborator

U S Army Medical Research & Development Command

[+1]

100 Clinical Results associated with Group B Meningococcal 44/76 MOS NOMV 5D Vaccine(WRAIR)

Login to view more data

100 Translational Medicine associated with Group B Meningococcal 44/76 MOS NOMV 5D Vaccine(WRAIR)

Login to view more data

100 Patents (Medical) associated with Group B Meningococcal 44/76 MOS NOMV 5D Vaccine(WRAIR)

Login to view more data

100 Deals associated with Group B Meningococcal 44/76 MOS NOMV 5D Vaccine(WRAIR)

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00248833 (CTgov)	Phase 1	Meningitis, Meningococcal	34	25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine (1) 25ug Group B Meningococcal 44/76 MOS NOMV 5D w/o Adjuvant)	fjuxkhkfmz = lhybhqmbdu zqvsletabo (nmqnwvgnwm, rndiobxbdh - hjgvhhhdbv) View more	-	29 Oct 2018
				25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine (2) 25ug Group B Meningococcal 44/76 MOS NOMV 5D With Adjuvant)	fjuxkhkfmz = mpafwehcbb zqvsletabo (nmqnwvgnwm, mssblldkfg - mxzlyrfsme) View more